Heat Biologics' Subsidiary Outlines Development of New Commercial/Biodefense Biomanufacturing Facility

  • Heat Biologics Inc HTBX announced a planned development partnership of its Scorpion Biological Services subsidiary with a private developer, the State of Kansas, and local and university affiliates.
  • The Company intends to utilize the new 500,000+ square foot facility for large molecule and biologics manufacturing, focusing on biodefense. 
  • In addition to servicing the Company's product pipeline, it plans to operate as a full-service Contract Development and Manufacturing Organization (CDMO) to provide third-party manufacturing services on a fee-for-service basis. 
  • Also Read: Heat Biologics Issues New PTX-35 Preclinical Data In Organ Transplantation, Update On HS-110.
  • Once fully operational, the new facility is expected to employ more than 500 individuals.
  • The facility is expected to have a billion-dollar economic impact within the State of Kansas.
  • The Manhattan facility is being designed to service up to 144,000 liters across 48 bioreactors.
  • Price Action: HTBX shares are up 1.07% at $2.83 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechGovernmentNewsPenny StocksHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!